BRPI0816790A8 - Composições farmacêuticas contendo toxóides a e b de clostridium difficile - Google Patents
Composições farmacêuticas contendo toxóides a e b de clostridium difficileInfo
- Publication number
- BRPI0816790A8 BRPI0816790A8 BRPI0816790A BRPI0816790A BRPI0816790A8 BR PI0816790 A8 BRPI0816790 A8 BR PI0816790A8 BR PI0816790 A BRPI0816790 A BR PI0816790A BR PI0816790 A BRPI0816790 A BR PI0816790A BR PI0816790 A8 BRPI0816790 A8 BR PI0816790A8
- Authority
- BR
- Brazil
- Prior art keywords
- clostridium difficile
- pharmaceutical compositions
- compositions containing
- toxoids
- compositions
- Prior art date
Links
- 241000193163 Clostridioides difficile Species 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 239000003053 toxin Substances 0.000 abstract 3
- 231100000765 toxin Toxicity 0.000 abstract 3
- 108700012359 toxins Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97249607P | 2007-09-14 | 2007-09-14 | |
| PCT/US2008/010767 WO2009035707A1 (en) | 2007-09-14 | 2008-09-15 | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0816790A2 BRPI0816790A2 (pt) | 2014-10-14 |
| BRPI0816790A8 true BRPI0816790A8 (pt) | 2017-05-16 |
Family
ID=40452372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0816790A BRPI0816790A8 (pt) | 2007-09-14 | 2008-09-15 | Composições farmacêuticas contendo toxóides a e b de clostridium difficile |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9320790B2 (https=) |
| EP (3) | EP2198007B1 (https=) |
| JP (3) | JP5503543B2 (https=) |
| KR (2) | KR20160005378A (https=) |
| CN (2) | CN106039299A (https=) |
| AU (1) | AU2008299885C1 (https=) |
| BR (1) | BRPI0816790A8 (https=) |
| CA (1) | CA2699435A1 (https=) |
| CY (1) | CY1119979T1 (https=) |
| DK (1) | DK2198007T3 (https=) |
| ES (2) | ES2657485T3 (https=) |
| HR (1) | HRP20180054T1 (https=) |
| HU (1) | HUE037932T2 (https=) |
| IL (1) | IL204366A (https=) |
| MX (1) | MX2010002815A (https=) |
| NO (1) | NO2198007T3 (https=) |
| PL (1) | PL2198007T3 (https=) |
| PT (1) | PT2198007T (https=) |
| RU (1) | RU2550271C2 (https=) |
| SI (1) | SI2198007T1 (https=) |
| WO (1) | WO2009035707A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2198007T3 (pl) | 2007-09-14 | 2018-03-30 | Sanofi Pasteur Biologics, Llc | Kompozycje farmaceutyczne zawierające toksoidy A i B Clostridium difficile |
| PL2753352T5 (pl) | 2010-09-03 | 2022-10-17 | Valneva Austria Gmbh | Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania |
| GB201105981D0 (en) * | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
| TWI815599B (zh) * | 2011-04-22 | 2023-09-11 | 美商惠氏有限責任公司 | 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法 |
| KR101135486B1 (ko) * | 2011-05-25 | 2012-04-13 | 함종욱 | 보툴리눔 에이형 독소의 액상제품 |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| CN104903349B (zh) | 2012-11-08 | 2018-10-19 | 十一生物治疗股份有限公司 | Il-6拮抗剂及其应用 |
| WO2014086787A1 (en) | 2012-12-05 | 2014-06-12 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| AP2015008733A0 (en) | 2013-03-14 | 2015-09-30 | Takeda Vaccines Inc | Compositions and methods for live, attenuated alphavirus formulations |
| KR20150133771A (ko) * | 2013-03-15 | 2015-11-30 | 사노피 파스퇴르 인코포레이티드 | 톡소이드, 조성물 및 관련 방법 |
| US20160045586A1 (en) * | 2013-03-15 | 2016-02-18 | Sanofi Pasteur, Inc. | Toxoid, Compositions and Related Methods |
| AU2014277981B2 (en) | 2013-06-14 | 2019-06-20 | Sanofi Pasteur Inc. | Compositions and methods of immunizing against C. difficile |
| RS57864B1 (sr) | 2013-06-17 | 2018-12-31 | De Staat Der Nederlanden Vert Door De Minister Van Vws Ministerie Van Volksgezondheid Welzijn En Spo | Postupci za sprečavanje agregacije virusnih komponenti |
| US9930893B2 (en) * | 2014-02-10 | 2018-04-03 | The Johns Hopkins University | Inhibitors of DXP synthase and methods of use thereof |
| JP6594438B2 (ja) | 2014-11-07 | 2019-10-23 | セセン バイオ， インコーポレイテッド | 改善されたｉｌ−６抗体 |
| WO2016187073A1 (en) | 2015-05-15 | 2016-11-24 | Sanofi Pasteur Inc. | Methods for immunizing against clostridium difficile |
| BE1023343B1 (nl) * | 2015-05-20 | 2017-02-09 | Mycartis Nv | Opslagbuffer |
| CN108718522A (zh) | 2016-02-23 | 2018-10-30 | 赛森生物股份有限公司 | Il-6拮抗剂制剂及其用途 |
| KR102480965B1 (ko) | 2016-09-13 | 2022-12-26 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
| CN112512480B (zh) * | 2018-05-21 | 2024-10-01 | 中外制药株式会社 | 被封入玻璃容器的冷冻干燥制剂 |
| WO2021255690A2 (en) * | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| AU2023393199A1 (en) * | 2022-12-13 | 2025-05-29 | Pfizer Inc. | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879218A (en) | 1982-09-13 | 1989-11-07 | Virginia Tech Intellectual Properties, Inc. | Antibody for C.difficile |
| US5736139A (en) | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
| JPH03193735A (ja) | 1989-12-22 | 1991-08-23 | Shionogi & Co Ltd | グリコペプチド系抗生物質の安定化組成物 |
| ZA927923B (en) * | 1991-10-16 | 1993-04-26 | Schering Corp | Lipophilic oligosaccharide antibiotic salt compositions. |
| WO1994000481A1 (en) | 1992-06-23 | 1994-01-06 | Associated Synapse Biologics | Pharmaceutical composition containing botulinum b complex |
| US5562909A (en) | 1993-07-12 | 1996-10-08 | Massachusetts Institute Of Technology | Phosphazene polyelectrolytes as immunoadjuvants |
| US5902565A (en) * | 1993-12-24 | 1999-05-11 | Csl Limited | Spray dried vaccine preparation comprising aluminium adsorbed immunogens |
| US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| JPH08333277A (ja) | 1995-06-05 | 1996-12-17 | Hoechst Japan Ltd | ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤 |
| JPH11510793A (ja) * | 1995-07-07 | 1999-09-21 | オラバックス インク． | 胃腸病に対する鼻腔内ワクチン接種 |
| US5932223A (en) | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| ES2276448T3 (es) * | 1997-06-20 | 2007-06-16 | Intervet International Bv | Vacuna contra clostridium perfringens. |
| US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| EP2305303A3 (en) * | 1997-10-20 | 2013-11-13 | Sanofi Pasteur Biologics Co. | Immunization against Clostridium difficile disease |
| EP1568378B1 (en) | 1997-10-20 | 2016-03-16 | Sanofi Pasteur Biologics, LLC | Immunization against Clostridium difficile disease |
| US6013635A (en) * | 1998-05-28 | 2000-01-11 | Synsorb Biotech, Inc. | Treatment of C. difficile toxin B associated conditions |
| JP2000117967A (ja) * | 1998-10-16 | 2000-04-25 | Fuji Photo Film Co Ltd | インクジェット記録方法 |
| FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
| PT1187629E (pt) * | 1999-04-19 | 2005-02-28 | Glaxosmithkline Biolog Sa | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador |
| US6599715B1 (en) * | 1999-05-12 | 2003-07-29 | The Regents Of The University Of California | Real time viability detection of bacterial spores |
| US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| CN101721362B (zh) | 2002-02-14 | 2018-07-03 | 中外制药株式会社 | 包含抗体的溶液制剂 |
| WO2003088946A1 (en) * | 2002-04-19 | 2003-10-30 | The Regents Of The University Of Michigan | Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens |
| US20040235139A1 (en) * | 2002-12-23 | 2004-11-25 | Demain Arnold L. | Clostridium difficile culture and toxin production methods |
| DE10333317A1 (de) | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| EP1686137A4 (en) | 2003-10-09 | 2009-10-28 | Chugai Pharmaceutical Co Ltd | Method of stabilizing protein solutions |
| EP2266599B1 (en) * | 2004-07-26 | 2014-04-16 | Merz Pharma GmbH & Co. KGaA | Therapeutic composition with a botulinum neurotoxin |
| US20060099169A1 (en) | 2004-10-13 | 2006-05-11 | Ilypsa, Inc. | Toxin binding compositions |
| FR2881139A1 (fr) * | 2005-01-26 | 2006-07-28 | Agronomique Inst Nat Rech | Composition pour la lyophilisation de proteines |
| US8137677B2 (en) | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| BRPI0613001B8 (pt) | 2005-10-06 | 2021-05-25 | Allergan Inc | composições farmacêuticas de toxina clostrídica estabilizada por uma não-proteína |
| US20090324647A1 (en) * | 2005-10-11 | 2009-12-31 | Borodic Gary E | Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use |
| MX2009004862A (es) | 2006-11-07 | 2009-07-17 | Sanofi Pasteur Biologics Co | Estabilizacion de vacunas por liofilizacion. |
| PL2198007T3 (pl) | 2007-09-14 | 2018-03-30 | Sanofi Pasteur Biologics, Llc | Kompozycje farmaceutyczne zawierające toksoidy A i B Clostridium difficile |
| UA105508C2 (uk) * | 2008-12-03 | 2014-05-26 | Бьорінгер Інгельхайм Ветмедіка Гмбх | Спосіб одержання вакцини проти clostridium difficile |
-
2008
- 2008-09-15 PL PL08830210T patent/PL2198007T3/pl unknown
- 2008-09-15 KR KR1020157036693A patent/KR20160005378A/ko not_active Abandoned
- 2008-09-15 ES ES08830210.4T patent/ES2657485T3/es active Active
- 2008-09-15 PT PT88302104T patent/PT2198007T/pt unknown
- 2008-09-15 CN CN201610227574.1A patent/CN106039299A/zh active Pending
- 2008-09-15 CN CN200880116603.0A patent/CN101855336B/zh active Active
- 2008-09-15 EP EP08830210.4A patent/EP2198007B1/en not_active Not-in-force
- 2008-09-15 RU RU2010114730/10A patent/RU2550271C2/ru not_active IP Right Cessation
- 2008-09-15 ES ES16174817T patent/ES3001561T3/es active Active
- 2008-09-15 WO PCT/US2008/010767 patent/WO2009035707A1/en not_active Ceased
- 2008-09-15 DK DK08830210.4T patent/DK2198007T3/en active
- 2008-09-15 HR HRP20180054TT patent/HRP20180054T1/hr unknown
- 2008-09-15 US US12/677,864 patent/US9320790B2/en active Active
- 2008-09-15 HU HUE08830210A patent/HUE037932T2/hu unknown
- 2008-09-15 BR BRPI0816790A patent/BRPI0816790A8/pt not_active IP Right Cessation
- 2008-09-15 EP EP24220340.4A patent/EP4537849A3/en active Pending
- 2008-09-15 SI SI200831906T patent/SI2198007T1/en unknown
- 2008-09-15 EP EP16174817.3A patent/EP3124044B8/en active Active
- 2008-09-15 NO NO08830210A patent/NO2198007T3/no unknown
- 2008-09-15 MX MX2010002815A patent/MX2010002815A/es unknown
- 2008-09-15 AU AU2008299885A patent/AU2008299885C1/en not_active Ceased
- 2008-09-15 JP JP2010524889A patent/JP5503543B2/ja active Active
- 2008-09-15 CA CA2699435A patent/CA2699435A1/en not_active Abandoned
- 2008-09-15 KR KR1020107007994A patent/KR101679812B1/ko not_active Expired - Fee Related
-
2010
- 2010-03-09 IL IL204366A patent/IL204366A/en active IP Right Grant
-
2013
- 2013-11-22 JP JP2013241821A patent/JP6258674B2/ja active Active
-
2016
- 2016-03-29 US US15/083,428 patent/US9687541B2/en active Active
- 2016-10-31 JP JP2016212540A patent/JP2017052773A/ja active Pending
-
2017
- 2017-06-26 US US15/632,480 patent/US10639362B2/en active Active
-
2018
- 2018-01-23 CY CY20181100084T patent/CY1119979T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0816790A8 (pt) | Composições farmacêuticas contendo toxóides a e b de clostridium difficile | |
| BR112017013661A8 (pt) | Conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica | |
| BR112018077266A2 (pt) | composições compreendendo cepas bacterianas | |
| TNSN07387A1 (en) | C.perfringens alpha toxoid vaccine | |
| BR112014029762A2 (pt) | composição contendo n-metil-n-acilglucamina | |
| MA43518B1 (fr) | 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase | |
| PE20142115A1 (es) | Composiciones de neisseria meningitidis y metodos de las mismas | |
| MA47664A1 (fr) | Anticorps anti-c10orf54 et leurs utilisations | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| EP3845241A8 (en) | Long lasting effect of new botulinum toxin formulations | |
| BR112014014410A2 (pt) | composições e métodos que compreendem uma variante de enzima lipolítica | |
| MX351074B (es) | Vacunas contra clostridium difficile que comprenden toxinas recombinantes. | |
| WO2011153513A3 (en) | Nanoemulsion composition containing vitamin k | |
| BR112012019997A2 (pt) | composições de cuidado oral | |
| BR112015008419A2 (pt) | composição imunogênica, e, vacina | |
| EA201001479A1 (ru) | Вакцина | |
| EP3878445A3 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| BR112015023332A2 (pt) | Toxóide, composições e método relacionados | |
| BR112014013876A2 (pt) | vacina à base de toxina de clostridium difficile | |
| MX2015012833A (es) | Composiciones antibioticas de ceftolozano. | |
| IN2014DN09791A (https=) | ||
| MX364946B (es) | Sistema adyuvante mejorado para la administración de vacunas orales. | |
| BR112019004303A2 (pt) | composição de conjugados multivalentes de polissacarídeo capsular pneumocócico-proteína portadora e uso da mesma | |
| BR112015030331A2 (pt) | derivados de succinato | |
| BR112014020184A8 (pt) | Preparação farmacêutica que contém anlodipina e ra-mipril |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: SANOFI PASTEUR BIOLOGICS, LLC (US) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 12A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2598 DE 20-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |